[{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Evofem Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"1","companyTruncated":"Evofem Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Population Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lubrizol Expands Partnership with the Population Council","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Segesterone Acetate","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Lubrizol Life Science Health","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lubrizol Life Science Health \/ Population Council","highestDevelopmentStatusID":"1","companyTruncated":"Lubrizol Life Science Health \/ Population Council"},{"orgOrder":0,"company":"Iconovo","sponsor":"Monash University","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iconovo Signs Agreement for Development of Inhaled Oxytocin in ICOone For Maternal Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Iconovo","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iconovo \/ Monash University","highestDevelopmentStatusID":"1","companyTruncated":"Iconovo \/ Monash University"},{"orgOrder":0,"company":"AT Research Partners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novel Contraceptive by AT Research Partners Promises Efficacy, Access and Safety for Women Using Nanotechnology","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Halogenated Fullerene Nanoparticle","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"AT Research Partners","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AT Research Partners \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AT Research Partners \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Eunice Kennedy Shriver National Institute Of Child Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem\u00ae Targeting Polycystic Ovary Syndrome as an Indication","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Brown Adipose-derived Stem Cells","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biorestorative Therapies \/ Eunice Kennedy Shriver National Institute Of Child Health","highestDevelopmentStatusID":"1","companyTruncated":"Biorestorative Therapies \/ Eunice Kennedy Shriver National Institute Of Child Health"},{"orgOrder":0,"company":"Heranova Lifesciences","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$13.5 million","upfrontCash":"Undisclosed","newsHeadline":"Heranova Lifesciences Debuts with $13.5 Million Seed and Seed+ Round Funding to Offer Integrated Clinical Solutions to Women's Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Heranova Lifesciences","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Heranova Lifesciences \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Heranova Lifesciences \/ Pivotal bioVenture Partners"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Heranova Lifesciences

U.S.A

Discovery on Target

Not Confirmed

02

Biorestorative Therapies

U.S.A

Discovery on Target

Not Confirmed

03

AT Research Partners

Country

Discovery on Target

Not Confirmed

04

Iconovo

Sweden

Discovery on Target

Not Confirmed

05

Lubrizol Life Science Health

U.S.A

Discovery on Target

Not Confirmed

06

Evofem Biosciences

U.S.A

Discovery on Target

Not Confirmed